Abingdon Health PLC (ABDX) AI Stock Analysis

• Market Cap: £13.55M
• Dividend Yield: N/A
• Average Volume (3M): 94.22K
• Price to Earnings (P/E): ―
• Beta (1Y): >-0.01
• Revenue Growth: 27.60%
• EPS Growth: 1.35%
• Country: UK
• Employees: 113
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 193,630,810
• 10 Day Avg. Volume: 34,546
• 30 Day Avg. Volume: 94,224
• PEG Ratio: 0.13
• Price to Book (P/B): 12.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 43.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: 7.50p ▲(7.14%Upside)

The overall score reflects strong technical momentum and positive corporate developments, offset by significant financial and valuation challenges. While strategic partnerships and contracts promise growth, profitability and liquidity issues present risks that temper the stock's attractiveness.

Abingdon Health PLC Business Overview & Revenue Model

Company Description

Abingdon Health PLC (ABDX) is a UK-based company specializing in the development and manufacture of rapid diagnostic testing solutions. It operates primarily in the healthcare and biotechnology sectors, offering a range of lateral flow tests for various applications, including human health, animal health, and environmental testing. Abingdon Health leverages its expertise in lateral flow technology to provide innovative, accurate, and cost-effective diagnostic products and services.

How the Company Makes Money

Abingdon Health PLC generates revenue through the development, manufacturing, and sale of lateral flow diagnostic tests. The company offers its products directly to healthcare providers, distributors, and other stakeholders in the healthcare sector. Additionally, Abingdon Health engages in contract manufacturing partnerships where it produces bespoke diagnostic solutions for third-party clients. Revenue is also derived from research and development services provided to external organizations, where Abingdon Health's expertise in lateral flow technology is utilized to develop custom diagnostic solutions. Strategic collaborations and partnerships with healthcare organizations further contribute to its revenue streams by expanding market reach and enhancing product offerings.

Abingdon Health PLC Financial Statement Overview

Summary

Abingdon Health PLC shows promising revenue growth and improved gross profit margins, but faces significant profitability challenges. The balance sheet reflects moderate leverage, but negative ROE suggests inefficiency in generating returns on equity. Cash flow metrics indicate a need for improved cash generation and management.

Income Statement

The company's revenue has shown significant growth over the past year with a 51.7% increase from 2023 to 2024. Gross profit margin improved significantly to 59.98%, indicating better cost management. However, the company remains unprofitable with a negative net profit margin of -20.72% and negative EBIT margin of -22.38%, suggesting ongoing challenges in achieving sustainable profitability.

Balance Sheet

The debt-to-equity ratio is relatively moderate at 0.47, indicating a balanced approach to leverage. However, the return on equity (ROE) is negative at -56.53%, highlighting profitability challenges. The equity ratio is 44.18%, showing a reasonable level of equity financing, but there is room for improvement in asset utilization and profitability.

Cash Flow

Free cash flow has deteriorated, with a significant decline in free cash flow from positive to negative over the past year. The operating cash flow to net income ratio is negative, indicating challenges in cash generation relative to reported losses. Free cash flow to net income ratio is also negative, pointing to difficulties in maintaining liquidity.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	6.82M	6.13M	4.04M	2.83M	11.62M	5.24M
Gross Profit	3.18M	3.68M	1.40M	-5.23M	3.39M	4.09M
EBITDA	-2.06M	-916.00K	-2.81M	-19.98M	-6.07M	-2.84M
Net Income	-2.59M	-1.27M	-3.45M	-21.26M	-6.97M	-3.37M
Balance Sheet
Total Assets	9.82M	5.09M	6.06M	12.77M	33.23M	10.97M
Cash, Cash Equivalents and Short-Term Investments	3.67M	1.44M	3.24M	2.40M	4.98M	4.39M
Total Debt	1.01M	1.05M	1.02M	1.28M	1.50M	4.77M
Total Liabilities	3.40M	2.84M	3.05M	6.34M	11.90M	8.22M
Stockholders Equity	6.42M	2.25M	3.01M	6.43M	21.33M	2.75M
Cash Flow
Free Cash Flow	-2.63M	-1.70M	845.00K	-8.49M	-20.13M	445.00K
Operating Cash Flow	-2.61M	-1.66M	1.00M	-7.74M	-12.88M	2.10M
Investing Cash Flow	-1.22M	-23.00K	-156.00K	-760.00K	-7.28M	-1.94M
Financing Cash Flow	5.50M	-114.00K	-7.00K	5.92M	20.74M	3.37M

Abingdon Health PLC Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ABDX, the sentiment is Positive. The current price of 7 is above the 20-day moving average (MA) of 6.90, above the 50-day MA of 6.40, and below the 200-day MA of 7.46, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 61.09 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ABDX.

Abingdon Health PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	66 Neutral	£13.55M	―	-62.83%	―	27.60%	1.35%
IHC	60 Neutral	£20.17M	―	-65.64%	―	-16.51%	-1655.56%
Sector *	59 Neutral	£5.89B	9.26	-57.69%	4.75%	14.48%	-6.99%
GDR	55 Neutral	£8.75M	―	-321.90%	―	125.37%	22.47%
PRM	44 Neutral	£9.00M	―		―	-2.80%	-38.55%

Abingdon Health PLC Corporate Events

Abingdon Health Secures €2 Million Contract for Diagnostic Test Development

Abingdon Health PLC has secured a €2 million contract with a European biotech company for the development and regulatory approval of a companion diagnostic test. This contract highlights the company’s comprehensive CDMO services, which include development, scale-up, technical transfer, and regulatory support. The project is expected to take 24 months and emphasizes Abingdon’s ability to manage complex diagnostic development processes effectively. This win underscores the company’s strong market position and its appeal as a one-stop partner for diagnostic solutions, bolstered by recent acquisitions and the launch of Abingdon Analytical.

Abingdon Health Strengthens US Ties with Key Appointment

Abingdon Health plc has announced the appointment of Chris Yates, President of Abingdon Health Inc., as a Director of Find Out From Home LLC (FOFH), in which Abingdon holds a 19% share. This strategic partnership, initially announced in March 2024, involves a $2 million contract for the development and regulatory approval of STD self-tests. The collaboration aims to enhance Abingdon’s presence in the US market and expand its product offerings in the STD testing sector.

Abingdon Health Partners with Okos Diagnostics for Avian Flu Test Kits

Abingdon Health PLC has announced a strategic partnership with Okos Diagnostics to develop and commercialize avian flu (H5N1) lateral flow test kits for both bovine and human health applications. This collaboration aims to address the growing threat of H5N1, as highlighted by recent outbreaks in the U.S., by leveraging Okos’ innovative diagnostic technology and Abingdon’s manufacturing and distribution capabilities. The partnership grants Abingdon exclusive global distribution rights, potentially enhancing its market position and offering significant benefits to stakeholders by providing rapid testing solutions to mitigate the risk of a pandemic.

Abingdon Health PLC Awards Share Options to Key Management

Abingdon Health PLC has announced the awarding of share options under its Long Term Incentive Plan (LTIP) to certain directors and senior management. This move aims to incentivize and retain key personnel by aligning their interests with those of the company’s shareholders. The options, which are nil cost, will vest by June 2027, contingent upon meeting specific total shareholder return criteria. This strategic initiative is expected to enhance the company’s operational stability and align management’s goals with shareholder interests, potentially impacting the company’s market position positively.